通过新抗原驱动的T细胞受体隔离,为肝细胞癌解锁基于T细胞的新型免疫疗法
Panagiota Maravelia1,2, Haidong Yao1,2, Curtis Cai3
1Division of Clinical Microbiology,Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden.
Gut
|January 20, 2025
概括
研究人员在肝细胞癌 (HCC) 患者中确定了新抗原反应性T细胞. 肝炎和淋巴结产生了有前途的T细胞和T细胞受体 (TCRs),用于未来的HCC免疫疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 基因组学就是基因组学.
背景情况:
- 瘤透T细胞在癌症免疫和进展中起着双重作用.
- 肝细胞癌 (HCC) 呈现出独特的,免疫抑制的微环境,限制了当前免疫治疗的疗效.
研究的目的:
- 鉴定晚期HCC患者的反应性T细胞群,尽管存在免疫抑制性瘤微环境.
- 分析瘤中的T细胞反应,肝炎和肝脏排水的淋巴结.
主要方法:
- 新抗原预测和对已识别的点进行T细胞反应性测试.
- 单细胞RNA测序以对抗原经验T细胞进行分析.
- 孤立的新抗原反应性T细胞的T细胞受体 (TCR) 测序.
主要成果:
- 确定了542个候选新抗原;78个加上11个热点目标被选择用于刺激.
- 证实了T细胞对14个点的反应性,其中大多数反应性细胞来自肝炎和淋巴结.
- 肝脏冲洗T细胞作为细胞毒性特征的中心/效应记忆 (CD4+),淋巴结T细胞作为组织内存 (CD4+/CD8+),具有耗尽的特征.
结论:
- 新抗原反应性T细胞在HCC微环境中表现出不同的功能特征.
- 肝炎和瘤排水淋巴结是HCC免疫疗法的反应性T细胞和TCR的潜在来源.
更多相关视频
相关概念视频
01:27Tumor Immunotherapy
468
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
468
01:22T Cell Activation and Clonal Selection
646
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
646